Investigating the role of specific enzymes in bladder cancer development
Official title: Targeting APOBEC3-induced squamous differentiation in bladder cancer
Funded at Univ of North Carolina Chapel Hill · NIH-11133494 · Data updated 2026-11-12
This study is looking at how certain enzymes might play a role in bladder cancer, and it's using a special mouse model to find out how these enzymes cause changes that can lead to cancer, with the hope of discovering new treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $514,582 |
| NIH project number | 1R01CA292625-01A1 |
| Project ID | NIH-11133494 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with bladder cancer, particularly those with urothelial carcinoma.
✕Less likely to help
Patients with non-cancerous bladder conditions or those with other types of cancer may not receive benefit from this research.
What this research studies
This research focuses on understanding how enzymes from the APOBEC3 family contribute to the development and progression of bladder cancer, particularly urothelial carcinomas. By using a novel mouse model, researchers will explore the mechanisms by which these enzymes induce mutations that lead to cancer. The study aims to identify potential therapeutic targets by examining the effects of APOBEC3 on tumor formation and differentiation in bladder cancer. Patients may benefit from insights gained that could lead to new treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for treating bladder cancer.
How similar studies have gone: Previous research has shown that targeting mutational processes in cancer can lead to significant advancements in treatment, suggesting this approach may also yield promising results.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Kim, William Y. — Univ of North Carolina Chapel Hill
- Study coordinator: Kim, William Y.
Related research
Other NIH-funded projects on the same topics.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Understanding why bladder cancer spreads and resists treatment
This grant studies how advanced bladder cancer changes and spreads across the body, aiming to uncover why it’s hard to treat.
-
Molecular clues to bladder cancer cell changes and therapy response
This NIH grant looks at how bladder cancer cells change their identity and how that affects response to treatment, with a focus on aggressive neuroendocrine variants.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.